Cargando…

The Systemic Inflammation Response Index as an Independent Predictor of Survival in Breast Cancer Patients: A Retrospective Study

There is a close relationship between inflammatory cells and tumors, but the pathways that connect the two remain unclear. This research explores the clinical and prognostic value of the systemic inflammation response index (SIRI) in breast cancer patients. The study included 477 breast cancer patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Mengliu, Chen, Li, Kong, Xiangyi, Wang, Xiangyu, Fang, Yi, Li, Xingrui, Wang, Jing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8918696/
https://www.ncbi.nlm.nih.gov/pubmed/35295846
http://dx.doi.org/10.3389/fmolb.2022.856064
_version_ 1784668787637747712
author Zhu, Mengliu
Chen, Li
Kong, Xiangyi
Wang, Xiangyu
Fang, Yi
Li, Xingrui
Wang, Jing
author_facet Zhu, Mengliu
Chen, Li
Kong, Xiangyi
Wang, Xiangyu
Fang, Yi
Li, Xingrui
Wang, Jing
author_sort Zhu, Mengliu
collection PubMed
description There is a close relationship between inflammatory cells and tumors, but the pathways that connect the two remain unclear. This research explores the clinical and prognostic value of the systemic inflammation response index (SIRI) in breast cancer patients. The study included 477 breast cancer patients who underwent neoadjuvant chemotherapy and 308 breast cancer patients who did not in our center between January 1998 and December 2016. Optimal SIRI threshold values were determined using the receiver operating characteristic curve (ROC). Patients were then reclassified as SIRI ≥0.80 group (High SIRI group) and SIRI <0.80 group (Low SIRI group). The outcomes were analyzed by statistical methods. The univariate and multivariate analyses demonstrated that SIRI independently predicted survival in breast cancer. The disease-free survival (DFS) and overall survival (OS) in patients with low SIRI scores were significantly longer in contrast to those with high SIRI scores (41.50 vs. 37.63 months, and 64.57 vs. 58.42 months). Further subgroup analyses revealed that low SIRI score patients who also had either early breast cancer, advanced breast cancer, or different molecular subtypes also possessed longer mean survival time of DFS and OS in contrast to those with high SIRI levels (χ2 = 2.379, p = 0.123, and χ2 = 5.153, p = 0.023; χ2 = 11.080, p = 0.0009 and χ2 = 15.900, p < 0.0001; χ2 = 16.020, p < 0.0001 and χ2 = 22.050, p < 0.0001, respectively). SIRI serves as an easily accessible, replicable, and minimally invasive prognostic tool in breast cancer patients. Lower SIRI scores were predictive of a longer DFS and OS after surgery in breast cancer patients. SIRI may serve as a marker to guide clinical management and prognostication of breast cancer.
format Online
Article
Text
id pubmed-8918696
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-89186962022-03-15 The Systemic Inflammation Response Index as an Independent Predictor of Survival in Breast Cancer Patients: A Retrospective Study Zhu, Mengliu Chen, Li Kong, Xiangyi Wang, Xiangyu Fang, Yi Li, Xingrui Wang, Jing Front Mol Biosci Molecular Biosciences There is a close relationship between inflammatory cells and tumors, but the pathways that connect the two remain unclear. This research explores the clinical and prognostic value of the systemic inflammation response index (SIRI) in breast cancer patients. The study included 477 breast cancer patients who underwent neoadjuvant chemotherapy and 308 breast cancer patients who did not in our center between January 1998 and December 2016. Optimal SIRI threshold values were determined using the receiver operating characteristic curve (ROC). Patients were then reclassified as SIRI ≥0.80 group (High SIRI group) and SIRI <0.80 group (Low SIRI group). The outcomes were analyzed by statistical methods. The univariate and multivariate analyses demonstrated that SIRI independently predicted survival in breast cancer. The disease-free survival (DFS) and overall survival (OS) in patients with low SIRI scores were significantly longer in contrast to those with high SIRI scores (41.50 vs. 37.63 months, and 64.57 vs. 58.42 months). Further subgroup analyses revealed that low SIRI score patients who also had either early breast cancer, advanced breast cancer, or different molecular subtypes also possessed longer mean survival time of DFS and OS in contrast to those with high SIRI levels (χ2 = 2.379, p = 0.123, and χ2 = 5.153, p = 0.023; χ2 = 11.080, p = 0.0009 and χ2 = 15.900, p < 0.0001; χ2 = 16.020, p < 0.0001 and χ2 = 22.050, p < 0.0001, respectively). SIRI serves as an easily accessible, replicable, and minimally invasive prognostic tool in breast cancer patients. Lower SIRI scores were predictive of a longer DFS and OS after surgery in breast cancer patients. SIRI may serve as a marker to guide clinical management and prognostication of breast cancer. Frontiers Media S.A. 2022-02-28 /pmc/articles/PMC8918696/ /pubmed/35295846 http://dx.doi.org/10.3389/fmolb.2022.856064 Text en Copyright © 2022 Zhu, Chen, Kong, Wang, Fang, Li and Wang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Molecular Biosciences
Zhu, Mengliu
Chen, Li
Kong, Xiangyi
Wang, Xiangyu
Fang, Yi
Li, Xingrui
Wang, Jing
The Systemic Inflammation Response Index as an Independent Predictor of Survival in Breast Cancer Patients: A Retrospective Study
title The Systemic Inflammation Response Index as an Independent Predictor of Survival in Breast Cancer Patients: A Retrospective Study
title_full The Systemic Inflammation Response Index as an Independent Predictor of Survival in Breast Cancer Patients: A Retrospective Study
title_fullStr The Systemic Inflammation Response Index as an Independent Predictor of Survival in Breast Cancer Patients: A Retrospective Study
title_full_unstemmed The Systemic Inflammation Response Index as an Independent Predictor of Survival in Breast Cancer Patients: A Retrospective Study
title_short The Systemic Inflammation Response Index as an Independent Predictor of Survival in Breast Cancer Patients: A Retrospective Study
title_sort systemic inflammation response index as an independent predictor of survival in breast cancer patients: a retrospective study
topic Molecular Biosciences
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8918696/
https://www.ncbi.nlm.nih.gov/pubmed/35295846
http://dx.doi.org/10.3389/fmolb.2022.856064
work_keys_str_mv AT zhumengliu thesystemicinflammationresponseindexasanindependentpredictorofsurvivalinbreastcancerpatientsaretrospectivestudy
AT chenli thesystemicinflammationresponseindexasanindependentpredictorofsurvivalinbreastcancerpatientsaretrospectivestudy
AT kongxiangyi thesystemicinflammationresponseindexasanindependentpredictorofsurvivalinbreastcancerpatientsaretrospectivestudy
AT wangxiangyu thesystemicinflammationresponseindexasanindependentpredictorofsurvivalinbreastcancerpatientsaretrospectivestudy
AT fangyi thesystemicinflammationresponseindexasanindependentpredictorofsurvivalinbreastcancerpatientsaretrospectivestudy
AT lixingrui thesystemicinflammationresponseindexasanindependentpredictorofsurvivalinbreastcancerpatientsaretrospectivestudy
AT wangjing thesystemicinflammationresponseindexasanindependentpredictorofsurvivalinbreastcancerpatientsaretrospectivestudy
AT zhumengliu systemicinflammationresponseindexasanindependentpredictorofsurvivalinbreastcancerpatientsaretrospectivestudy
AT chenli systemicinflammationresponseindexasanindependentpredictorofsurvivalinbreastcancerpatientsaretrospectivestudy
AT kongxiangyi systemicinflammationresponseindexasanindependentpredictorofsurvivalinbreastcancerpatientsaretrospectivestudy
AT wangxiangyu systemicinflammationresponseindexasanindependentpredictorofsurvivalinbreastcancerpatientsaretrospectivestudy
AT fangyi systemicinflammationresponseindexasanindependentpredictorofsurvivalinbreastcancerpatientsaretrospectivestudy
AT lixingrui systemicinflammationresponseindexasanindependentpredictorofsurvivalinbreastcancerpatientsaretrospectivestudy
AT wangjing systemicinflammationresponseindexasanindependentpredictorofsurvivalinbreastcancerpatientsaretrospectivestudy